Golimumab (anti-TNF monoclonal antibody): where we stand today

doi:10.1080/21645515.2020.1836919

Review

. 2021 Jun 3;17(6):1586-1598.

doi: 10.1080/21645515.2020.1836919. Epub 2020 Dec 28.

Golimumab (anti-TNF monoclonal antibody): where we stand today

Ana Teresa Melo^{1

2}, Raquel Campanilho-Marques^{1

2}, João Eurico Fonseca^{1

2}

Affiliations

¹ Rheumatology Department, Hospital De Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.
² Rheumatology Research Unit, Instituto De Medicina Molecular João Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa, Lisbon, Portugal.

PMID: 33369527
PMCID: PMC8115761
DOI: 10.1080/21645515.2020.1836919

Review

Golimumab (anti-TNF monoclonal antibody): where we stand today

Ana Teresa Melo et al. Hum Vaccin Immunother. 2021.

. 2021 Jun 3;17(6):1586-1598.

doi: 10.1080/21645515.2020.1836919. Epub 2020 Dec 28.

Authors

Ana Teresa Melo^{1

2}, Raquel Campanilho-Marques^{1

2}, João Eurico Fonseca^{1

2}

Affiliations

¹ Rheumatology Department, Hospital De Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.
² Rheumatology Research Unit, Instituto De Medicina Molecular João Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa, Lisbon, Portugal.

PMID: 33369527
PMCID: PMC8115761
DOI: 10.1080/21645515.2020.1836919

Abstract

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases. Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TNF monoclonal antibody that acts primarily by targeting and neutralizing TNF, thus preventing inﬂammation. It is approved for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Nonradiographic axial Spondyloarthritis, Juvenile Idiopathic Arthritis, and Ulcerative Colitis. Clinical trials are also being conducted in other conditions. This review charts the clinical development of golimumab and outlines the data that support its potential use across several Immune-mediated inflammatory diseases.

Keywords: Immune-mediated inflammatory diseases; golimumab; tnf inhibitors.

PubMed Disclaimer

Cited by

The role of inflammation in autoimmune disease: a therapeutic target.
Xiang Y, Zhang M, Jiang D, Su Q, Shi J. Xiang Y, et al. Front Immunol. 2023 Oct 4;14:1267091. doi: 10.3389/fimmu.2023.1267091. eCollection 2023. Front Immunol. 2023. PMID: 37859999 Free PMC article. Review.
Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study.
Xia W, Zhou L, Gao W, Zhang Y, Si F, Bai F, Zhang Z, Wang W, Chen G, Gao C, Li X, Yue T. Xia W, et al. Medicine (Baltimore). 2024 Feb 23;103(8):e36982. doi: 10.1097/MD.0000000000036982. Medicine (Baltimore). 2024. PMID: 38394542 Free PMC article.
Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations.
McIntosh SM, Kerut C, Hollenshead PP, Askins DH, Mansourian K, Palowsky ZR, Allampalli V, Ahmadzadeh S, Shekoohi S, Kaye AD. McIntosh SM, et al. Life (Basel). 2023 Jul 21;13(7):1601. doi: 10.3390/life13071601. Life (Basel). 2023. PMID: 37511975 Free PMC article. Review.
Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era.
Iliadis AS, Koletsa T, Vounotrypidis P, Fassas A, Apostolidis A, Apostolidis S, Fotiadou A, Hytiroglou P. Iliadis AS, et al. Cureus. 2024 Nov 6;16(11):e73121. doi: 10.7759/cureus.73121. eCollection 2024 Nov. Cureus. 2024. PMID: 39651014 Free PMC article.
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.
Kawczak P, Feszak IJ, Bączek T. Kawczak P, et al. J Clin Med. 2025 Mar 19;14(6):2107. doi: 10.3390/jcm14062107. J Clin Med. 2025. PMID: 40142915 Free PMC article. Review.

See all "Cited by" articles

References

1. Pelechas E, Voulgari PV, Drosos AA.. Golimumab for rheumatoid arthritis. J Clin Med. 2019. March 20;8(3):387. doi:10.3390/jcm8030387. - DOI - PMC - PubMed
1. Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G, Tam S, Sague S, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. mAbs. 2010. August;2(4):428–39. doi:10.4161/mabs.12304. - DOI - PMC - PubMed
1. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol Orlando Fla. 2008. February;126(2):121–36. doi:10.1016/j.clim.2007.08.013. - DOI - PMC - PubMed
1. Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017. August;10(8):899–910. doi:10.1080/17512433.2017.1329009. - DOI - PMC - PubMed
1. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56–63. doi:10.1016/j.cyto.2016.08.014. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Pelechas E, Voulgari PV, Drosos AA.. Golimumab for rheumatoid arthritis. J Clin Med. 2019. March 20;8(3):387. doi:10.3390/jcm8030387. - DOI - PMC - PubMed

[2] Pelechas E, Voulgari PV, Drosos AA.. Golimumab for rheumatoid arthritis. J Clin Med. 2019. March 20;8(3):387. doi:10.3390/jcm8030387. - DOI - PMC - PubMed

[3] Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G, Tam S, Sague S, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. mAbs. 2010. August;2(4):428–39. doi:10.4161/mabs.12304. - DOI - PMC - PubMed

[4] Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G, Tam S, Sague S, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. mAbs. 2010. August;2(4):428–39. doi:10.4161/mabs.12304. - DOI - PMC - PubMed

[5] Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol Orlando Fla. 2008. February;126(2):121–36. doi:10.1016/j.clim.2007.08.013. - DOI - PMC - PubMed

[6] Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol Orlando Fla. 2008. February;126(2):121–36. doi:10.1016/j.clim.2007.08.013. - DOI - PMC - PubMed

[7] Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017. August;10(8):899–910. doi:10.1080/17512433.2017.1329009. - DOI - PMC - PubMed

[8] Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017. August;10(8):899–910. doi:10.1080/17512433.2017.1329009. - DOI - PMC - PubMed

[9] Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56–63. doi:10.1016/j.cyto.2016.08.014. - DOI - PubMed

[10] Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56–63. doi:10.1016/j.cyto.2016.08.014. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Golimumab (anti-TNF monoclonal antibody): where we stand today

Affiliations

Golimumab (anti-TNF monoclonal antibody): where we stand today

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials